5043-79-8

Basic information

• Product Name: METHYL 5-CHLORO-2-HYDROXY-3-NITROBENZOATE
• Synonyms: METHYL 5-CHLORO-2-HYDROXY-3-NITROBENZOATE;benzoic acid, 5-chloro-2-hydroxy-3-nitro-, Methyl ester;5-chloro-2-hydroxy-3-nitrobenzoic acid methyl ester;5-chloro-2-hydroxy-3-nitro-benzoic acid methyl ester
• CAS NO: 5043-79-8
• Molecular Formula: C₈H₆ClNO₅
• Molecular Weight: 231.58994
• Mol File: 5043-79-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 108-110 °C
• Boiling Point: 293.9°Cat760mmHg
• Flash Point: 131.5°C
• Appearance: /
• Density: 1.548g/cm³
• Vapor Pressure: 0.000957mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 6.06±0.38(Predicted)
• CAS DataBase Reference: METHYL 5-CHLORO-2-HYDROXY-3-NITROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-CHLORO-2-HYDROXY-3-NITROBENZOATE(5043-79-8)
• EPA Substance Registry System: METHYL 5-CHLORO-2-HYDROXY-3-NITROBENZOATE(5043-79-8)

Safety Data

• Hazardous Substances Data: 5043-79-8(Hazardous Substances Data)

Usage

General Description

Methyl 5-chloro-2-hydroxy-3-nitrobenzoate is a chemical compound with the molecular formula C8H6ClNO5. It is a derivative of benzoic acid, and its structure consists of a benzene ring with a chlorine atom, a hydroxyl group, and a nitro group attached to it. METHYL 5-CHLORO-2-HYDROXY-3-NITROBENZOATE is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis and as a reagent in chemical research. Additionally, methyl 5-chloro-2-hydroxy-3-nitrobenzoate may have potential biological activities and pharmacological properties that make it valuable for medical research and drug development.

InChI:InChI=1/C8H6ClNO5/c1-15-8(12)5-2-4(9)3-6(7(5)11)10(13)14/h2-3,11H,1H3

Upstream product

• 4068-78-4 methyl 5-chloro-2-hydroxybenzoate 

Downstream Products

• 123040-16-4 Azasetron hydrochloride 
• 579525-14-7 C₁₆H₁₃ClN₂O₄ 
• 1313588-05-4 C₂₄H₂₁Cl₂F₃N₄O₄ 
• 123040-44-8 C₁₂H₁₂ClNO₇ 
• 1228005-51-3 (E)-1-(3-chloro-2-hydroxy-3-nitrophenyl)-3-(2-chloro-6-ethoxyquinolin-3-yl)prop-2-en-1-one 
• 579525-13-6 5-chloro-2-trifluoromethanesulfonyloxy-3-nitrobenzoic acid methyl ester 
• 141762-14-3 6-Chloro-3-oxo-4-phenethyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide 
• 141762-13-2 4-Benzyl-6-chloro-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide 
• 141762-06-3 6-Chloro-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-benzyl-piperidin-4-yl)-amide 
• 141762-05-2 6-Chloro-4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid (1-benzyl-piperidin-3-yl)-amide 
• 123040-69-7 azasetron 
• 141761-83-3 6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxylic acid methyl ester 
• 141761-94-6 6-Chloro-3-oxo-4-phenethyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid methyl ester 
• 141762-01-8 6-Chloro-3-oxo-4-phenethyl-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid 

Relevant articles and documents

Novel preparation method of azasetron hydrochloride

The invention provides a novel preparation method of azasetron hydrochloride, belonging to the technical field of medicine synthesis. According to the method, methyl 5-chlorosalicylate is used as a raw material; after acetic anhydride nitrification and stannous chloride reduction at room temperature, dimethyl carbonate is used as a methylation reagent, and an intermediate V (6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxylic acid methyl ester) is synthesized by adopting a one-pot method; the intermediate V is hydrolyzed to obtain 6-chloro-4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-formic acid (VI); and the compound reacts with free 3-aminoquinuclidine dihydrochloride for 1 h under the catalysis of TBTU to form a salt so as to obtain I (azasetron hydrochloride). According to the method, the yield of each step is high; aftertreatment is simple; the reaction time of each step is short; conditions are mild; low-toxicity environment-friendly reagents are adopted; energy consumption is reduced; cost is saved; and industrial production is better facilitated.

BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes mellitus.

Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists

A series of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives was synthesized and evaluated for serotonin-3 (5-HT3) receptor antagonistic activity assessed by their ability to antagonize the von Bezold-Jarish (BJ) effect in rats. Derivatives bearing 1-azabicyclo[2.2.2]oct-3-yl moiety as a basic function attached to the carboxamide at position 8 showed more potent antagonistic activity than those bearing the other three basic moieties. Structure activity relationships of this series showed that methyl and chloro groups were more effective as substituents at positions 4 and 6, respectively. The representative compound 15 (Y-25130) in this series showed potent antagonistic activity on the BJ effect (ED50 = 1.3 μg/kg i.v.), high affinity for 5-HT3 receptor (K(i) = 2.9 nM) and complete protection against cisplatin-induced emesis in dogs at a dose of 0.1 mg/kg i.v.